These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35100236)

  • 1. Varenicline nasal spray (Tyrvaya) for dry eye disease.
    Med Lett Drugs Ther; 2021 Dec; 63(1639):198-199. PubMed ID: 35100236
    [No Abstract]   [Full Text] [Related]  

  • 2. Perfluorohexyloctane ophthalmic solution (Miebo) for dry eye disease.
    Med Lett Drugs Ther; 2024 Jan; 66(1694):13-14. PubMed ID: 38212258
    [No Abstract]   [Full Text] [Related]  

  • 3. Loteprednol 0.25% (Eysuvis) for dry eye disease.
    Med Lett Drugs Ther; 2021 May; 63(1624):75-77. PubMed ID: 33976092
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety, adherence and discontinuation in varenicline solution nasal spray clinical trials for dry eye disease.
    Hauswirth SG; Kabat AG; Hemphill M; Somaiya K; Hendrix LH; Gibson AA
    J Comp Eff Res; 2023 Jun; 12(6):e220215. PubMed ID: 37096956
    [No Abstract]   [Full Text] [Related]  

  • 5. Matching-adjusted indirect comparison of phase 3 clinical trial outcomes of OC-01 (varenicline solution) nasal spray and lifitegrast 5% ophthalmic solution for the treatment of dry eye disease.
    White DE; Hendrix LH; Sun L; Tam I; Macsai M; Gibson AA
    J Manag Care Spec Pharm; 2023 Jan; 29(1):69-79. PubMed ID: 36030415
    [No Abstract]   [Full Text] [Related]  

  • 6. Quintessence of currently approved and upcoming treatments for dry eye disease.
    Patil S; Sawale G; Ghuge S; Sathaye S
    Graefes Arch Clin Exp Ophthalmol; 2024 Aug; ():. PubMed ID: 39215848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine 0.09% solution (Cequa) for dry eye Disease.
    Med Lett Drugs Ther; 2019 Jul; 61(1577):116-118. PubMed ID: 31381551
    [No Abstract]   [Full Text] [Related]  

  • 8. Varenicline Solution Nasal Spray: A Review in Dry Eye Disease.
    Frampton JE
    Drugs; 2022 Sep; 82(14):1481-1488. PubMed ID: 36197638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial.
    Wirta D; Vollmer P; Paauw J; Chiu KH; Henry E; Striffler K; Nau J;
    Ophthalmology; 2022 Apr; 129(4):379-387. PubMed ID: 34767866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: The MYSTIC study.
    Quiroz-Mercado H; Hernandez-Quintela E; Chiu KH; Henry E; Nau JA
    Ocul Surf; 2022 Apr; 24():15-21. PubMed ID: 34920097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matching-adjusted indirect comparison of phase 3 clinical trial outcomes: OC-01 (varenicline solution) nasal spray and cyclosporine a 0.05% ophthalmic emulsion for the treatment of dry eye disease.
    Visco DM; Hendrix LH; Sun L; Tam I; Macsai M; Gibson AA
    J Manag Care Spec Pharm; 2022 Aug; 28(8):892-902. PubMed ID: 35687793
    [No Abstract]   [Full Text] [Related]  

  • 12. Dry Eye Disease: Focus on Prescription Therapy.
    Marshall LL; Hayslett RL
    Sr Care Pharm; 2023 Jun; 38(6):239-251. PubMed ID: 37231571
    [No Abstract]   [Full Text] [Related]  

  • 13. The efficacy and safety of varenicline nasal spray for the management of dry eye signs: a systematic review and meta-analysis.
    Bashrahil B; Taher N; Alzahrani Z; Alnabihi A; Aldahlawi A; Alkhathlan M; Alghamdi S
    BMC Ophthalmol; 2023 Jul; 23(1):319. PubMed ID: 37452334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bilateral Effect of OC-01 (Varenicline Solution) Nasal Spray for Treatment of Signs and Symptoms in Individuals with Mild, Moderate, and Severe Dry Eye Disease.
    Katz J; Periman LM; Maiti S; Sarnicola E; Hemphill M; Kabat AG; Hendrix LH; Shah P; Gibson A
    Clin Ther; 2022 Nov; 44(11):1463-1470. PubMed ID: 36763994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Single-dose OC-02 (Simpinicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The PEARL Phase II Randomized Trial.
    Torkildsen GL; Pattar GR; Jerkins G; Striffler K; Nau J
    Clin Ther; 2022 Sep; 44(9):1178-1186. PubMed ID: 35965109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of bilateral OC-01 (varenicline solution) nasal spray in alleviating signs and symptoms of dry eye disease: A systematic review.
    Ballesteros-Sánchez A; Borroni D; De-Hita-Cantalejo C; Sánchez-González MC; Sanchez-Gomez S; Rocha-de-Lossada C; Sánchez-González JM
    Cont Lens Anterior Eye; 2024 Feb; 47(1):102097. PubMed ID: 38065797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does Dry Eye Disease Severity Impact Efficacy of Varenicline Solution Nasal Spray on Sign and Symptom Treatment Outcomes?
    Sheppard JD; O'Dell LE; Karpecki PM; Raizman MB; Whitley WO; Blemker G; Hemphill M; Hendrix LH; Gibson A; Macsai M
    Optom Vis Sci; 2023 Feb; 100(2):164-169. PubMed ID: 36728653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease.
    Wirta D; Torkildsen GL; Boehmer B; Hollander DA; Bendert E; Zeng L; Ackermann M; Nau J
    Cornea; 2022 Oct; 41(10):1207-1216. PubMed ID: 36107843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I, Open-label, Randomized, 2-Way Crossover Study to Evaluate the Relative Bioavailability of Intranasal and Oral Varenicline.
    Nau J; Wyatt DJ; Rollema H; Crean CS
    Clin Ther; 2021 Sep; 43(9):1595-1607. PubMed ID: 34456060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loteprednol etabonate: a formulation for short-term use in inflammatory flares in dry eye disease.
    Paton DM
    Drugs Today (Barc); 2022 Feb; 58(2):77-84. PubMed ID: 35188142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.